Dinutuximab
NCI-2012-03125
Phase 2 mab completed
Quick answer
Dinutuximab for Ganglioneuroblastoma is a Phase 2 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Ganglioneuroblastoma
- Phase
- Phase 2
- Modality
- mab
- Status
- completed